<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959918</url>
  </required_header>
  <id_info>
    <org_study_id>SEL-212/201</org_study_id>
    <nct_id>NCT02959918</nct_id>
  </id_info>
  <brief_title>Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout &amp; Elevated Blood Uric Acid</brief_title>
  <official_title>An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Selecta Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Selecta Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label multicenter study to evaluate the safety and tolerability of multiple&#xD;
      doses(3 monthly IV infusions) of SEL-212 ( a combination of pegsiticase( SEL-037) and&#xD;
      SVP-rapamycin (SEL-110)) followed by multiple doses (2 monthly IV infusions) of pegsiticase&#xD;
      (SEL-037) alone for a total of 5 treatment cycles in subjects with symptomatic gout and&#xD;
      hyperuricemia. Additional subjects will be treated with multiple doses( 5 monthly IV&#xD;
      infusions) of pegsiticase (SEL-037) alone.&#xD;
&#xD;
      Subjects will be monitored for safety endpoints through the 5th treatment cycle plus 30 days&#xD;
      .Pharmacokinetic samples will drawn a pre-determined time points in addition to weekly serum&#xD;
      uric acid levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label multicenter study to evaluate the safety and tolerability of multiple&#xD;
      doses(3 monthly IV infusions) of SEL-212( a combination of pegsiticase( SEL-037) and&#xD;
      SVP-rapamycin (SEL-110)) followed by multiple doses (2 monthly IV infusions) of pegsiticase&#xD;
      (SEL-037) alone for a total of 5 treatment cycles in subjects with symptomatic gout and&#xD;
      hyperuricemia. Additional subjects will be treated with multiple doses( 5 monthly IV&#xD;
      infusions) of pegsiticase (SEL-037) alone.&#xD;
&#xD;
      Uricase is an enzyme that converts uric acid to the readily soluble allantoin that is then&#xD;
      excreted and SEL-110 is designed to prevent unwanted anti-drug-antibodies (ADAs) from&#xD;
      forming. All subjects will be monitored for safety and tolerability to drug throughout the&#xD;
      study on a weekly schedule. Pharmacokinetic and pharmacodynamic parameters will at specific&#xD;
      timepoints to monitor for continued efficacy. Pharmacodynamic parameters measured include&#xD;
      uric acid levels and levels of ADAs.&#xD;
&#xD;
      The study duration per enrolled subject will be approximately 6 months including a 1 month&#xD;
      screening period followed by 5 treatment cycles and an end of treatment visit which will&#xD;
      occur 30 days after the last IV infusion .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of multiple intravenous infusions of SEL-212 as assessed by the frequency of drug related adverse events, graded by severity</measure>
    <time_frame>Five monthly infusions</time_frame>
    <description>To determine the safety and tolerability of 3 monthly infusions of SEL-212 followed by 2 monthly infusions of SEL-037 (pegsiticase) as assessed by frequency of drug related adverse events, graded by severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of SEL-037 (pegsiticase) after multiple monthly IV infusions with or without SEL-110</measure>
    <time_frame>5 months</time_frame>
    <description>Measurement of the pharmacokinetics of SEL-037, with or without SEL-110, for 30 days after multiple monthly IV infusions by area under the blood concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) (ability to reduce circulating uric acid) of SEL-037 after multiple monthly IV infusions with or without SEL-110</measure>
    <time_frame>5 months</time_frame>
    <description>Measurement of the pharmacodynamics (ability to reduce circulating uric acid) of SEL-037 after multiple monthly infusions with or without SEL-110 by measurement of blood uric acid levels for 30 days post infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of SEL-037 after multiple monthly IV infusions with our without SEL-110</measure>
    <time_frame>5 months</time_frame>
    <description>Immunogenicity of SEL-037 after multiple monthly IV infusions with or without SEL-110 by measurement of anti-drug antibody levels over 30 days post each infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetics (PK) of rapamycin after multiple IV infusions of SEL-110 with multiple IV infusions of SEL-037.</measure>
    <time_frame>5 months</time_frame>
    <description>To determine the pharmacokinetics of rapamycin after multiple I V infusions of SEl-212 by area under the blood concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The effect on uric acid deposits and/or total body uric acid deposited as measured by Dual Energy Computed Tomography scan of multiple doses of SEL-037 alone or multiple doses of SEL-212 plus additional doses of SEL-037.</measure>
    <time_frame>Baseline and 5 months</time_frame>
    <description>To measure the change in uric acid deposits in specified joints from beginning to end of treatment</description>
  </other_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Gout Chronic</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>SEL-037 Pegsiticase LD(low dose) alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-037 Pegsiticase HD(high dose) alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase LD &amp; SEL-110 (1a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (1b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase LD &amp; SEL-110 (2a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (2b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (3a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (3b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (4a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (4b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (5a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (5b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (6a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (6b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEL-212</intervention_name>
    <description>SEL-212</description>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (1b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (2b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (3a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (3b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (4a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (4b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (5a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (5b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (6a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (6b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase LD &amp; SEL-110 (1a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase LD &amp; SEL-110 (2a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEL-037</intervention_name>
    <description>SEL-037, biologic</description>
    <arm_group_label>SEL-037 Pegsiticase HD(high dose) alone</arm_group_label>
    <arm_group_label>SEL-037 Pegsiticase LD(low dose) alone</arm_group_label>
    <other_name>pegsiticase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SVP-rapamycin (SEL-110)</intervention_name>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (1b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (2b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (3a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (3b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (4a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (4b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (5a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (5b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (6a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase HD &amp; SEL-110 (6b)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase LD &amp; SEL-110 (1a)</arm_group_label>
    <arm_group_label>SEL-212, Pegsiticase LD &amp; SEL-110 (2a)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult (age 21-75 inclusive) men and women of non child bearing potential with&#xD;
             established or symptomatic gout which is defined as having at least ONE of any of the&#xD;
             3 following factors:&#xD;
&#xD;
               1. ≥ 1 tophus&#xD;
&#xD;
               2. 1 gout flare within the last 6 months&#xD;
&#xD;
               3. Chronic gouty arthropathy&#xD;
&#xD;
          2. Screening serum uric acid of &gt;6ng/dL&#xD;
&#xD;
          3. On a gout flare prophylactic regimen for 7 days prior to first dose&#xD;
&#xD;
          4. Willing to provide written informed consent prior to first study procedure is&#xD;
             performed.&#xD;
&#xD;
          5. Understands and is willing and able to comply with study requirements, including the&#xD;
             schedule of follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of anaphylaxis or severe allergic reaction.&#xD;
&#xD;
          2. History of an allergy to pegylated products.&#xD;
&#xD;
          3. Women of child bearing potential, Defined as:&#xD;
&#xD;
               -  &lt;6 weeks after surgical bilateral salpingooperhectony with or without&#xD;
                  hysterectomy&#xD;
&#xD;
               -  Pre or perimenopausal ( &lt; less than 24 months of natural amenorrhea)&#xD;
&#xD;
          4. Initiation or change in dose of hormone-replacement therapy for menopausal women less&#xD;
             than 1 month prior to the Screening Visit or during the Screening Phase would be&#xD;
             exclusionary. If after being on a stable dose of hormone-replacement therapy for one&#xD;
             month the patient may be considered for the study if she continues to meet all other&#xD;
             inclusion and exclusion criteria&#xD;
&#xD;
          5. Uncontrolled diabetes with baseline HbA1c ≥8%;&#xD;
&#xD;
          6. Glucose-6-phosphate dehydrogenase deficiency;&#xD;
&#xD;
          7. Uncontrolled hypertension&#xD;
&#xD;
          8. Ongoing treatment for arrhythmia, including placement of an implantable defibrillator;&#xD;
&#xD;
          9. History of coronary artery disease, including myocardial infarction;&#xD;
&#xD;
         10. Congestive heart failure, New York Heart Association Class III or IV;&#xD;
&#xD;
         11. ECG with evidence of prior myocardial infarction, clinically significant arrhythmia,&#xD;
             or other abnormalities that, in the opinion of the investigator, are consistent with&#xD;
             significant underlying cardiac disease;&#xD;
&#xD;
         12. History of hematological or autoimmune disorders, is immunosuppressed or&#xD;
             immunocompromised;&#xD;
&#xD;
         13. Prior exposure to any experimental or marketed uricase (e.g., rasburicase (Elitek,&#xD;
             Fasturtec), pegloticase (Krystexxa®), pegsiticase (SEL-037)&#xD;
&#xD;
         14. History of malignancy within the last 5 years other than basal skin cancer;&#xD;
&#xD;
         15. Subjects who, in the opinion of the investigator, present with a condition that would&#xD;
             compromise their safety or that would make study completion unlikely.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri West Research Associates LLC</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irvine Center for Clinical Research Inc.</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants LLC</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East-West Medical Research Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-MARC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triad Clinical Trials LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Horizons Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 6, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>April 2, 2021</submitted>
    <returned>April 28, 2021</returned>
    <submitted>June 28, 2021</submitted>
    <returned>July 19, 2021</returned>
    <submitted>August 4, 2021</submitted>
    <returned>August 25, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

